Explore the words cloud of the TT4CL project. It provides you a very rough idea of what is the project "TT4CL" about.
The following table provides information about the project.
ST GEORGE'S HOSPITAL MEDICAL SCHOOL
|Coordinator Country||United Kingdom [UK]|
|Total cost||0 €|
|EC max contribution||3˙753˙135 € (0%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-05-01 to 2023-04-30|
Take a look of project's partnership.
|1||ST GEORGE'S HOSPITAL MEDICAL SCHOOL||UK (LONDON)||coordinator||1˙273˙863.00|
|2||AVIVIA BEHEER BV||NL (NIJMEGEN)||participant||591˙000.00|
|3||EBERHARD KARLS UNIVERSITAET TUEBINGEN||DE (TUEBINGEN)||participant||580˙150.00|
|4||LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER||UK (LONDON)||participant||569˙196.00|
|5||TEHRAN UNIVERSITY OF MEDICAL SCIENCES||IR (TEHRAN)||participant||371˙375.00|
|6||OBLITA THERAPEUTICS||BE (ZOERSEL)||participant||367˙550.00|
Cutaneous leishmaniasis (CL) is a poverty related, neglected tropical disease, which is without an effective and cheap systemic treatment. The aim of TT4CL is to develop a new orally available drug for treatment of CL aimed towards registration with stringent regulatory authorities. Oleylphosphocholine (OlPC), regarded as a new drug by the FDA, is structurally related to the anti-leishmanial miltefosine. It is being developed as an immediate-release tablet for the treatment of CL and, currently, is the only systemically delivered drug specifically being developed for this indication. OlPC is active in vitro and in vivo against different CL-causing Leishmania parasite species and shows curative advantage over miltefosine in rodent models of leishmaniasis. The primary objective of this study is to complete the pre-clinical package that is essential for the subsequent clinical development of OlPC. The project will aim to optimize the synthesis and formulation of OlPC, including stability testing that is appropriate for tropical climates. It will include in vitro drug sensitivity analyses in parasites causing CL (Leishmania tropica and L. major) in the Islamic Republic of Iran, with our endemic-country partner. Comparative studies in animal models with existing anti-leishmanial compounds will establish efficacy advantages and determine pharmacokinetic-pharmacodynamic relationships for OlPC. Phase 1 studies will confirm tolerability and pharmacokinetics of single doses and multiple dosing regimens. Results will be used to guide decisions by future partners on the clinical development of OlPC. This proposal directly addresses the priorities highlighted in this H2020 call. To our knowledge, we are the only consortium that is implementing this type of approach, and there is no other interest in the pharmaceutical sector to carry out a development programme for the oral treatment of CL.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TT4CL" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TT4CL" are provided by the European Opendata Portal: CORDIS opendata.
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
EXpanding Platforms for Efficacious mRNA TherapeuticsRead More